You are viewing: UK Veterinary Pharmaceuticals Market analysis

The UK Veterinary Pharmaceuticals Market was valued at $1042.1 Million in 2026 and projected to reach to $1416.6 Million by 2031, representing a compound annual growth rate of 6.3%. The UK veterinary pharmaceuticals market is positioned for steady growth through 2031, supported by rising pet ownership, increased spending on animal healthcare, and growing awareness of preventive medicine.

UK Veterinary Pharmaceuticals Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UK Veterinary Pharmaceuticals Market Trends and Insights

  • The UK market benefits from strong regulatory frameworks, high pet ownership rates, and increasing investment in animal health infrastructure.
  • The UK's established veterinary sector and growing demand for preventive care solutions are driving expansion across companion animal and livestock segments. Key drivers of growth in the UK include rising awareness of zoonotic diseases, increased spending on pet healthcare, and the adoption of advanced pharmaceutical formulations.
  • The UK market is characterized by a mature healthcare system with stringent quality standards that support premium-priced veterinary products.
  • Between 2026 and 2031, the UK is expected to see sustained demand for antimicrobials, vaccines, and specialty pharmaceuticals, supported by both private practice growth and government-backed animal health initiatives..

Key Market Statistics

  • CAGR (2026-2031) 6.3% CAGR
  • Market Size, 2026 ~USD 1042.1 Million
  • Forecast, 2031 ~USD 1416.6 Million
  • Country UK

UK Veterinary Pharmaceuticals Market Overview

Market Valuation Growth :

The UK veterinary pharmaceuticals market is valued at USD 1,042.1 million in 2026 and is projected to reach USD 1,416.6 million by 2031, demonstrating robust expansion driven by increasing pet healthcare spending and livestock disease management.

Strong Regulatory Environment :

The UK benefits from stringent regulatory frameworks and established veterinary oversight bodies that ensure high-quality pharmaceutical standards, creating a competitive advantage for compliant manufacturers and fostering market trust among practitioners.

High Pet Ownership Rates :

With one of Europe's highest pet ownership rates, the UK market experiences sustained demand for companion animal pharmaceuticals, including treatments for chronic conditions, preventive care, and emerging therapeutic areas.

Infrastructure Investment :

Increasing investment in UK animal health infrastructure, veterinary clinics, and diagnostic facilities supports market growth and enables adoption of advanced pharmaceutical solutions across companion and production animal segments.

UK Veterinary Pharmaceuticals Market Dynamics

  • The market benefits from a mature veterinary sector with established distribution networks and strong regulatory compliance standards.
  • Companion animal pharmaceuticals are expected to drive significant growth, particularly in areas such as pain management, dermatology, and behavioral treatments.
  • Additionally, livestock pharmaceutical demand remains stable due to the UK's substantial agricultural sector and stringent animal welfare regulations that mandate disease prevention and treatment protocols..

Related Ecosystem

Animal Health

Top Technologies
  • Polymerase Chain Reaction (PCR) Tests
  • Porcine
  • Immunodiagnostics
  • Lateral Flow Assays
  • Microarrays
Top Companies
  • Zoetis Inc.
  • Patterson Companies, Inc.
  • Virbac
  • Elanco Animal Health Incorporated
  • BOEHRINGER INGELHEIM GMBH

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Merck KGaA
    • Thermo Fisher Scientific Inc.
    • SANOFI
    • NOVARTIS
    • Pfizer Inc.

      Key Takeaways

      • The UK veterinary pharmaceuticals market will grow from USD 1,042.1M (2026) to USD 1,416.6M (2031) at a 6.3% CAGR.
      • The UK's mature regulatory environment and high pet ownership drive premium product adoption and market stability.
      • Rising UK demand for preventive care and antimicrobial solutions supports sustained pharmaceutical growth through 2031.
      • The UK market benefits from strong government support for animal health and increasing private veterinary practice investment.

      Veterinary Pharmaceuticals Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment ONLINE PHARMACIES/E-COMMERCE (Distribution Channel)
      Forecast Period 2026–2031
      Growth Rate CAGR of 6.3% from 2026 to 2031
      Largest Segment COMPANION ANIMALS (Animal Type)
      Market Size Base Year (Billions) ~USD 29.01 (2026)
      Revenue Forecast (Billions) ~USD 39.37 (2031)
      Segments Covered Product Type, Type, Route Of Administration, Formulation Type, Indication, Animal Type, Distribution Channel, End User

      UK Veterinary Pharmaceuticals Market Report Segmentation

      8 segment dimensions are covered across the global market.

      By Product Type

      • Drugs
      • Immunomodulators
      • Medicated Feed Additives
      • Monoclonal Antibodies

      By Type

      • Amino Acids
      • Anti-Bacterial Drugs
      • Anti-Cancer Drugs
      • Anti-Fungal Drugs
      • Anti-Inflammatory Drugs
      • Anti-Parasitic Drugs
      • Anti-Viral Drugs
      • Cardiovascular & Renal Drugs
      • Cardiovascular And Renal Drugs
      • Cats
      • Cattle
      • Dogs
      • Enzymes
      • Gastrointestinal Drugs
      • Horses
      • Minerals And Vitamins
      • Other Companion Animals
      • Other Drugs
      • Other Livestock Animals
      • Other Medical Feed Additives
      • Other Medicated Feed Additives
      • Poultry
      • Swine

      By Route Of Administration

      • Oral
      • Other Routes Of Administration
      • Parenteral
      • Topical

      By Formulation Type

      • Aerosol/Spray
      • Liquid
      • Premix Formulations
      • Semi-Solid
      • Solid

      By Indication

      • Cardiovascular And Renal Diseases
      • Dermatological Diseases
      • Gastrointestinal Diseases
      • Infectious Diseases
      • Other Diseases
      • Pain Management

      By Animal Type

      • Companion Animals
      • Livestock Animals

      By Distribution Channel

      • Direct Sales
      • Online Pharmacies/
      • Online Pharmacies/E-Commerce
      • Retail Pharmacies
      • Veterinary Hospital Pharmacies

      By End User

      • Home Care Settings
      • Livestock Farms
      • Other End Users
      • Veterinary Hospitals & Clinics

      Target Audience

      • Pharmaceutical Manufacturers : UK and international veterinary pharmaceutical companies need detailed market intelligence to identify growth opportunities, assess competitive positioning, and develop targeted product strategies for the British market.
      • Veterinary Distributors & Retailers : Wholesale distributors and veterinary pharmacy retailers require market forecasts and segment analysis to optimize inventory management, negotiate supplier contracts, and capitalize on emerging demand trends.
      • Investment & Private Equity Firms : Investors evaluating UK veterinary healthcare assets need comprehensive market sizing, growth projections, and profitability drivers to assess investment returns and identify acquisition targets in the sector.
      • Veterinary Practice Owners & Managers : Veterinary clinic operators need market insights on pharmaceutical trends, pricing dynamics, and treatment preferences to optimize product offerings, improve profitability, and enhance client satisfaction.
      • Market Research & Consulting Firms : Research organizations and consultants require UK-specific veterinary pharmaceutical data to support client advisory services, competitive benchmarking, and strategic planning across the animal health industry.

      Key Companies in the UK Veterinary Pharmaceuticals Market

      CompanyHQOwnershipStrongest segments
      ZOETIS INC.United StatesPublic CompanyCompanion animal therapeutics (parasiticides, dermatology, pain, other pharma),Livestock pharmaceuticals (vaccines, anti-infectives, other pharma),Diagnostics (point-of-care, instruments, reagents, reference labs),
      MERCK & CO., INCUnited StatesPublic CompanyOncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations, Lynparza co-commercialization),Vaccines (Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23),Cardiovascular, pulmonary hypertension, and specialty (Winrevair, Adempas/Verquvo, Ohtuvayre, Prevymis, Bridion, Dificid, Zerbaxa),
      ELANCO ANIMAL HEALTH INCORPORATEDUnited StatesPublic CompanyCompanion animal parasiticides (Seresto, K-9 Advantage, Advantix, Advocate, Credelio Family, Interceptor Plus, Drontal family),Companion animal vaccines and therapeutics (including Galliprant and vaccines portfolio),Cattle products (Rumensin, Baytril, Experior and related medicated feed additives, injectables, vaccines),
      VIRBACFrancePublic CompanyCompanion animal therapeutics (vaccines, antibiotics, anti-inflammatories, dermatology, dental, specialty),Parasiticides (incl. collars like Prevexto),Farm animal vaccines (incl. Suigen Entero 3, PCV2, Donoban),
      CEVAUnited StatesPublic Company5G/5G-A baseband DSP and RAN IP (PentaG-RAN, XC20/XC21/XC23, Ceva-BX2),Connectivity IP (Ceva-Waves Bluetooth, Wi-Fi, UWB, Links, DragonFly NB-IoT),Sensing, audio, and spatial software IP (SensPro, BX1, ClearVox, RealSpace, MotionEngine),
      VETOQUINOLFrancePublic CompanyCompanion animal therapeutics (mobility, pain, dermatology, behavior, internal medicine, cardio-nephrology),Livestock therapeutics (udder health, antibiotics, reproduction, internal medicine),Antiparasitics (companion and livestock),
      DECHRA PHARMACEUTICALS PLCUnited KingdomPrivate CompanyCompanion animal therapeutics,Food-producing animal products,Equine therapies,
      HESTER BIOSCIENCES LIMITEDIndiaPublic CompanyPoultry vaccines,Large animal vaccines,Veterinary pharmaceuticals (therapeutics),
      ANIMALCARE GROUP PLCUnited KingdomPublic CompanyCompanion animal pharmaceuticals (pain, endocrine, chronic care),Dental and joint health (Orozyme, Plaqtiv+, Cosequin),Equine pharmaceuticals and supplements,

      ZOETIS INC.

      Zoetis Inc. is a United States-based public company founded in 2012 that employs 14,500 people. The company operates in the animal health sector.

      MERCK & CO., INC

      Merck & Co., Inc. is a United States-based public company founded in 1891 with 74,000 employees. The company is a major pharmaceutical and healthcare organization.

      ELANCO ANIMAL HEALTH INCORPORATED

      Elanco Animal Health Incorporated is a United States-based public company founded in 1954 with 9,650 employees. The company specializes in animal health products and services.

      VIRBAC

      Virbac is a French public company founded in 1968 with 6,442 employees. The company operates in the animal health and veterinary pharmaceutical sector.

      CEVA

      Ceva is a United States-based public company founded in 1999 with 400 employees. The company operates in the animal health industry.

      VETOQUINOL

      Vetoquinol is a French public company founded in 1933 with 2,454 employees. The company specializes in veterinary pharmaceuticals and animal health products.

      DECHRA PHARMACEUTICALS PLC

      Dechra Pharmaceuticals PLC is a United Kingdom-based private company founded in 1997 with 2,457 employees. The company operates in the veterinary pharmaceutical sector.

      HESTER BIOSCIENCES LIMITED

      Hester Biosciences Limited is an India-based public company founded in 1987. The company operates in the animal health and veterinary pharmaceutical sector.

      ANIMALCARE GROUP PLC

      Animalcare Group PLC is a United Kingdom-based public company with 220 employees. The company operates in the animal health and veterinary pharmaceutical industry.

      Reasons to Buy this Report

      • Market-Specific Sizing & Forecasts : Access precise UK market valuations (2026: USD 1,042.1M; 2031: USD 1,416.6M) with detailed segment breakdowns by animal type, therapeutic category, and distribution channel tailored to the British veterinary landscape.
      • Regulatory & Compliance Insights : Understand UK-specific regulatory requirements, licensing pathways, and compliance standards set by the Veterinary Medicines Directorate (VMD) to navigate market entry and product approval efficiently.
      • Competitive Landscape Analysis : Identify leading UK and international pharmaceutical manufacturers, their market share, product portfolios, and strategic positioning within the UK veterinary sector to inform competitive strategy.
      • Growth Driver Identification : Discover key UK-specific growth catalysts including pet ownership trends, livestock disease prevalence, veterinary clinic expansion, and consumer spending patterns driving pharmaceutical demand.
      • Strategic Investment Guidance : Make informed decisions on market entry, partnership opportunities, and product development priorities based on comprehensive UK market dynamics, emerging segments, and long-term growth projections.

      Frequently asked questions

      What is the current size of the UK veterinary pharmaceuticals market?

      The UK veterinary pharmaceuticals market is valued at USD 1,042.1 million in 2026.

      What is the projected size of the UK veterinary pharmaceuticals market by 2031?

      The UK veterinary pharmaceuticals market is projected to reach USD 1,416.6 million by 2031.

      What is the CAGR for the UK veterinary pharmaceuticals market?

      The UK veterinary pharmaceuticals market is expected to grow at a compound annual growth rate (CAGR) of 6.3% from 2026 to 2031.

      What are the main drivers of growth in the UK veterinary pharmaceuticals market?

      Key growth drivers in the UK include rising pet ownership, increased spending on preventive care, growing awareness of zoonotic diseases, and strong regulatory support for animal health products.

      Which segments are driving the UK veterinary pharmaceuticals market?

      The UK market is driven by companion animal pharmaceuticals, livestock health products, vaccines, antimicrobials, and specialty formulations supported by both private and government-backed initiatives.

      RESEARCH METHODOLOGY

      This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

      Secondary Research

      This research study involved the usage of comprehensive secondary sources, directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet, white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the Veterinary Pharmaceuticals Market. It was also used to obtain important information about the key players, market classification, and segmentation according to industry trends to the bottommost level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

      Primary Research

      In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the Veterinary Pharmaceuticals Markets. Primary sources from the demand side include healthcare professionals from hospitals, ambulatory surgical centers, long-term care facilities, diagnostic imaging centers, outpatient clinics, and other end users.

      A breakdown of the primary respondents is provided below:

      Veterinary Pharmaceuticals Market Size, and Share

      Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.
      Note 2: Other Designations include sales managers, marketing managers, and product managers.
      Note 3: Tiers are defined based on a company’s total revenue as of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The total size of the veterinary pharmaceuticals market was determined through data triangulation across three approaches, as outlined below. After each approach, the weighted average of the three was calculated based on the level of assumptions used in each.

      Veterinary Pharmaceuticals Market : Top-Down and Bottom-Up Approach

      Veterinary Pharmaceuticals Market Top Down and Bottom Up Approach

      Data Triangulation

      After arriving at the market size, the total market was divided into several segments and subsegments. To complete the overall market engineering process and obtain exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed where applicable. The following figure shows the market validation, source structure, and data triangulation methodology implemented in the market engineering process.

      Market Definition

      The veterinary pharmaceuticals market comprises medicinal products used to prevent, control, and treat diseases in animals, excluding vaccines. It includes therapeutic drug classes such as anti-infectives (antibacterials, antivirals, antifungals, antiparasitic), anti-inflammatory drugs, hormonal therapies, dermatological drugs, cardiovascular drugs, gastrointestinal agents, and other prescription and over-the-counter pharmaceuticals. These products address indications including infectious diseases, dermatological disorders, reproductive health, metabolic diseases, and pain management, among others. The market covers both companion and livestock animals and is supplied through veterinary hospitals, clinics, pharmacies, and animal health distribution channels globally.

      Key Stakeholders

      • Veterinary Pharmaceutical Manufacturers (Branded & Generic Drug Manufacturers)
      • Veterinary Generic Drug Manufacturers
      • Veterinary Compounding Pharmacies
      • Veterinary Contract Manufacturing Organizations (CMOs)
      • Active Pharmaceutical Ingredient (API) Suppliers for Animal Health
      • Veterinary Hospitals and Specialty Veterinary Clinics
      • General Veterinary Practitioners
      • Livestock Farm Owners and Commercial Farm Operators
      • Companion Animal Owners (Pet Owners)
      • Veterinary Group Purchasing Organizations (GPOs)
      • Animal Health Distributors and Wholesalers
      • Veterinary Pharmacy Chains (Retail & Online)
      • E-Pharmacy Platforms for Animal Medicines
      • Regulatory Authorities (e.g., FDA-CVM, EMA, CDSCO, VMD)
      • Animal Health Contract Research Organizations (CROs)
      • Academic and Veterinary Research Institutes
      • Animal Health Insurance Providers (Pet Insurance Companies)
      • Feedlot and Integrated Livestock Production Companies
      • Animal Welfare Organizations

      Report Objectives

      • To define, describe, and forecast the veterinary pharmaceuticals market, product type, route of administration, formulation type, indication, animal type, distribution channel, end user, and region
      • To provide detailed information about the key factors influencing market growth, such as drivers, restraints, opportunities, challenges, and industry trends
      • To strategically analyze the regulatory scenario, value chain analysis, supply chain analysis, Porter’s Five Forces analysis, ecosystem analysis, trade analysis, pricing analysis,
      • patent analysis, impact of AI, trends/disruption impacting customers’ business in the market, and the impact of the 2025 US tariff on the market.
      • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall veterinary pharmaceuticals market
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To strategically profile the key players in this market and comprehensively analyze their market shares and core competencies.
      • To strategically analyze the veterinary pharmaceuticals market in five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
      • To track and analyze competitive developments such as product launches and approvals, acquisitions, partnerships, collaborations, and expansions in the veterinary pharmaceuticals market

      Available customizations:

      • Based on the given market data, MarketsandMarkets offers customizations tailored to your company’s specific needs. The following customization options are available for the report:

      Competitive Landscape Assesment

      • Market share analysis for the North America and Europe region, which provides market shares of the top 3–5 key players in the veterinary pharmaceuticals market
      • Competitive leadership mapping for established players in the US

      Regional Analysis

      • Further breakdown of the Rest of European veterinary pharmaceuticals market into Austria, Finland, the Netherlands, Switzerland, and others
      • Further breakdown of the Rest of Latin American veterinary pharmaceuticals market into Argentina, Colombia, Chile, and others

      Company Information

      • Detailed analysis and profiling of additional market players (up to 5)

       

      Get the Full Veterinary Pharmaceuticals Market Report

      Full forecast, segment splits, and company analysis for all Veterinary Pharmaceuticals Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status